HistoSonics Stock
Developing a non-invasive, autonomous robotic platform capable of destroying tissue at a sub-cellular level
Sign up today and learn more about HistoSonics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About HistoSonics Stock
HistoSonics, Inc. was created to advance the development of histotripsy, a science discovered and developed by leading scientists at the University of Michigan to provide improved therapies for patients. According to the company, its exclusive license to intellectual property, significant financial support, and strategic partnerships have helped HistoSonics develop Robotically Assisted Sonic Therapy (RAST)™, a novel beam therapy capable of destroying tissue at a sub-cellular level. HistoSonics’ team of specialists and industry leaders is based in Ann Arbor, Michigan.
Funding History
| February 2010 | $14.0M |
|---|---|
| May 2014 | $0 |
| December 2014 | $1.5M |
| September 2015 | $3.5M |
| March 2017 | $8.3M |
| July 2018 | $4.8M |
| April 2019 | $54.0M |
Management
VP of Regulatory & Clinical Affairs
Michael Daniel
CFO
Jon Freeman
VP of Research & Development
Joshua Stopek
VP of Operations
Daniel Bulver
President & CEO
Mike Blue
VP of Marketing
Josh King
Press
mpo-mag - Mar, 19 2024
HistoSonics' IDE Study of the Edison System Now Underwaybusinesswire - Feb, 16 2024
HistoSonics Awarded Key Position in UK’s Novel Innovation Programmpo-mag - Feb, 6 2024
HistoSonics Nabs Significant Reimbursement Gainsdbusiness - Jan, 10 2024
HistoSonics Launches New Liver Treatment Programsmassdevice - Dec, 24 2023
HistoSonics scores reimbursement win for sonic beam therapyEquityZen Recognized As:
